Prelude Capital Management’s SpringWorks Therapeutics SWTX Stock Holding History

Prelude Capital Management’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-171,716	Closed	-$8.07M	–	1373
2025 Q2	$8.07M	Buy	171,716 +140,533	+451%	+$6.25M	0.78%	15
2025 Q1	$1.38M	Buy	31,183 +14,746	+90%	+$679K	0.1%	220
2024 Q4	$594K	Sell	16,437 -28,056	-63%	-$980K	0.04%	537
2024 Q3	$1.43M	Buy	44,493 +28,056	+171%	+$1.05M	0.09%	294
2024 Q2	$619K	Hold	16,437	–	–	0.04%	452
2024 Q1	$809K	Buy	16,437 +2,736	+20%	+$126K	0.04%	454
2023 Q4	$500K	Buy	+13,701	New	+$358K	0.03%	516

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Prelude Capital Management's SWTX Position: Q3 2025 in Review

Prelude Capital Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 171,716 shares — an estimated $8.07M sold.

Prelude Capital Management first reported a position in SWTX in Q4 2023 and held it in 7 quarters. The position peaked at $8.07M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Prelude Capital Management reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Prelude Capital Management sold 171,716 SpringWorks Therapeutics shares in Q3 2025, an estimated $8.07M.
Prelude Capital Management first reported a position in SpringWorks Therapeutics in Q4 2023 and held it in 7 quarters.
Prelude Capital Management's SpringWorks Therapeutics position peaked at $8.07M in Q2 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.